ATL chairman and CEO Dennis Fill this month said he expects theFood and Drug Administration to approve within the next severalweeks the use of the company's flagship HDI 3000 scanner for differentiatingmalignant from benign solid breast lesions. ATL, of
ATL chairman and CEO Dennis Fill this month said he expects the
Food and Drug Administration to approve within the next several
weeks the use of the company's flagship HDI 3000 scanner for differentiating
malignant from benign solid breast lesions. ATL, of Bothell, WA,
already has FDA approval to differentiate solid breast lesions
using its older Ultramark 9 HDI scanner, and filed a supplemental
premarket approval application with the agency to extend the technique
to HDI 3000 (SCAN 4/24/96). Fill made the comments during a presentation
at the Bear Stearns Health Care Conference in New York City.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.